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ABSTRACT
In order to assure the safety and efficacy of the Chinese Medicines in Europe, the quality of TCM herbals should be guaranteed so that they
can be freely imported in the European Union and other Western European Countries which are signatories of the European Pharmacopoeia
Convention. Consequently, new Ph Eur TCM herbal drug Monographs should be elaborated, based on preexisting Monographs in the Chinese
Pharmacopoeia (ChP) 2010.
Such a program has been inaugurated in 2005 by the Ph Eur Groups of Experts 13 A and B (Phytochemistry). Since then good progress has
been made, elaborating of about one third of the originally proposed 100 TCM herbals being identified as important monographs for the
European Market. Taking into account the many challenges still laying ahead, the establishment of a specialized Working Party (WP) on TCM
with specialists and experts from many EU Member States has been decided by the Ph Eur Commission in 2008 which is highly active ever
since in the examination and elaboration of new TCM herbal drug monographs, primarily to assure the safety of the European patient and
further to provide quality parameters extremely important for all registration and licensing procedures of the respective National Authorities
all over Europe.
This paper is a survey of results and difficulties obtained so far which has been encountered meanwhile in the elaboration process by the
Ph Eur TCMWP of these monographs and will discuss these in detail. Moreover the role of Ph Eur TCMmonographs in the European community
is addressed.
Key words: European Pharmacopeia (Ph Eur), Chinese Pharmacopoeia (ChP), Traditional Chinese Medicine (TCM), TCM monographs,
herbal drugs and quality control
INTRODUCTION
Since ancient times, all cultures have developed health
care strategies, which are often characterized by a holistic
approach to living organisms. A holistic approach to living
organisms has been the basis of Traditional Chinese Medi-
cine (TCM) from its earliest years[1,2]. The TCM approach is
recognizing the uniqueness of each human being and the
necessity to develop a personalized medication to obtain
optimal results based on multi-component treatments[3].
Because of this specific feature, TCM becomes more and
more popular in treatment and prevention of diseases in
other cultures. In the past two decades public interest in
herbal therapies (Phytomedicine) has increased significantly
in Europe. Traditional Chinese herbal medicines including
Chinese crude herbal materials and manufactured herbal
products are a frequently used form of traditional medicines.
Currently, the practice of TCM is not only popular in China
and some Asian regions; but also it is appreciated worldwide.
A large-scale study of the Chinese population of Taiwan
showed that from 1996 to 2001, more than 60% of all subjects
have used Chinese medicine during a 6-year interval. TCMs
(85.9%) were the most common modality[4]. It was estimated
that more than 1.5 billion people all over the world are
trusting in the efficacy and safety of Chinese medicine[5]. In
the ‘Western World’, the term ‘alternative’ medicine is now
often replaced by ‘complementary’ medicine. This empha-
sizes the complimentary nature of TCM and Western medical
systems. The latest term ‘integrative’ medicine underpins the
gain that can be obtained when Western and complementary
modalities are used together[3]. Data provided by the Chinese
Import and Export Chamber of Commerce of Medicine and
Health Products shows yearly export sales of traditional
Chinese herbal medicinal products to the EU of approxi-
mately 12 million US dollars over the last four years suggest-
ing a significant amount of TCM products entering EU
market. In respect to this, quality control should be one of
the important aspects to guarantee the safe use of TCM
products for the patient.
The European Directorate for the Quality of Medicines
(EDQM) is an organization which belongs to the Council of
Europe (head quarter in Strasbourg, France) which is a
leading organization that protects public health by:
. enabling the development,
. supporting the implementation, and
. monitoring the application
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of quality standards for safe medicines and their safe use. Their
standards are recognized as a scientific benchmark world-
wide. The European Pharmacopoeia is legally binding in all
member states. The activities elaborating quality monographs
of Traditional Chinese Medicines for the European consu-
mers/ patients started in 2005 following a decision of the Ph
Eur Commission, which stated that monographs on herbal
drugs used in Traditional Chinese Medicine should be
developed to provide modern quality standards according to
the pre-existing Ph Eur standards. Following this decision in
2005, the existing groups of experts 13A and B (Phytochem-
istry) received a note from the Ph Eur Commission Secretariat
to include in their working program Chinese Medicines
products listed as monographs in the ChP 2005. It was then
stated that the elaboration of monographs on TCM herbals
should provide modern quality standards according to the Ph
Eur principles which should facilitate and encourage the use by
the practitioners and further to provide save and authorized
products to the patient.
From legal perspective, the Directive (Directive 2004/24/
EC) on Traditional Herbal Medicine Products existing in the
European Medicine Agency (EMA) should be the basis for
simplified registration procedures[6] from that time onward,
based on traditional use and ensuring quality and safety
without the need to prove efficacy by clinical studies of the
product. Therefore, elaboration of Ph Eur monographs for
TCM is fundamentally important for all quality parameters for
the TCM product intended to stay/entering the EU market.
Priority setting of TCM herbal drug candidates was
proposed according to a number of documented criteria such
as toxicity, risk of substitution, adulterations, volume of use
etc. A coordination with the work program of the Committee
on Herbal Traditional Products (HMP) of the EMA and the
existence of a monograph on a related herbal drug in the actual
Chinese Pharmacopeia (ChP) was an essential prerequisite. It
was also decided that herbal drug preparations and com-
pounded products should not be dealt with for the time being.
A priority setting of individual monograph candidates by
both groups 13A and B (expert groups working for European
herbal medicine monographs at EDQM) followed the criteria
such as order of overall importance in the EU, quality and
completeness of an existing monograph in ChP, and the
extent of use in the respective EU Member States and finally,
the availability of herbal drug samples on the European and
on the International Market.
Initially, more than 100 TCM herbal drug candidates
were proposed and out of these, about 75 TCM herbal drugs
were finally selected and put in the initial Working Program.
First start was made with an evaluation of existing ChP
monographs followed by an experimental reexamination of
the methods, in order to fulfill the guidelines of the Ph Eur.
With regard to these TCM herbal drugs the ChP Mono-
graphs could serve as a basis for the Ph Eur Monographs.
However, a number of issues had to be addressed since all Ph
Eur monographs have to take into account the relevant style
and quality parameters currently required for all Mono-
graphs of the Ph Eur.
ESTABLISHMENT OF THE TCM
WORKING PARTY BY THE PH EUR
COMMISSION (EDQM)
After an initial phase of about two years, the Group of
Experts 13A and 13B (European Scientists working at EDQM
for European herbal drugs) had to stop the activities in
elaborating Monographs on Traditional Chinese Medicine
Herbals. This was based on the annual reporting of the
Working Program to the European Pharmacopoeia Commis-
sion at EDQM, it was found that Groups 13A and 13B had
only the capacity to work on European Herbal Drugs. This
fact was the basis for the creation of a Working Party on
Traditional Chinese Medicine in 2008 by the Ph Eur
Commission at the EDQM.
Therefore, specialists from all EU Member States were
needed and the profile for experts and specialists was then
summarized by the European Pharmacopoeia Commission.
Consequently the experts/specialists should have:
. Current expertise in pharmaceutical and analytical
methods related to quality control of Herbal Drugs and
Herbal Drug Preparations and in development of control
methods.
. Access to laboratory facilities for verification of methods
proposed for inclusion of Monographs.
. Several years of experience in one or more of the
following fields:
– quality control of Herbal Drugs and Herbal Drug
Preparation
– involvement in market surveillance or regulatory
affairs oversight of imported TCM Herbal Drugs
– knowledge of cultivation, harvesting, conservation
– development of chromatographic separations sys-
tems for Herbal Drug constituents
– knowledge of use of TCM Herbal Drugs
According to these profile for experts and specialists, the
different National Authorities were asked to propose candi-
dates which were then nominated by the Ph Eur Commission
in the November 2007 Session. Nomination of experts and
specialists based on the proposals made by the National
Authorities of the EU Member States is carried out by the
Presidium of the Ph Eur Commission. Then the Commission
nominates the Chairman for the Working Party. The next
step was the definition of the Working Program for the
newly established TCM Working Party. It is important
to note that only the Ph Eur Commission has the right to
approve or remove items of the Working Program or to
approve requests for revisions.
In 2008, the official TCM working party with 18 scientists
with relevant scientific background as members plus the
Chairman of the Working Party was established at EDQM.
The members are officially elected by the delegations of the
European Member States with approval of Ph Eur commission
(Table 1). Since then, the scientific team has been working on
elaboration of TCM herbal drug monographs for Ph Eur.
According to the rules of procedure, the progress on the
Working Program is reviewed once a year by the Ph Eur
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Commission, usually in the March Session, where chairs have
to report regularly to the Commission about progress of the
Working Program, highlighting items and work that did not
fulfill the expected results with explanation of reasons. The
Chairman, with the support from the Secretariat at EDQM, is
responsible for the progress of the work allocated to each
Group of Experts or Working Party. In consultation with the
members in the Group of Experts or Working Party, the
Chairman establishes the working plan, and the distribution
of the work, in concern of the targets, to ensure that the
target deadlines are respected.
PROCEDURE FOR ELABORATION OF
PH EUR MONOGRAPHS
It should always be kept in mind that a Monograph from any
TCM herbal drug should be drafted with the same overall
structure as other European Pharmacopoeia Monographs,
based on the latest version of the Technical Guide for the
Elaboration of Monographs and on the Style Guide. It has to
be recalled that all tests and assay methods described in a
Monograph must be validated according to the procedures
dated in the Technical Guide. All the details of the general
Monograph on Herbal Drugs and Herbal Drug Preparations
must be taken into consideration for the elaboration of the
individual TCM Herbal Drug Monographs.
The general procedures for establishment of a monograph
at Ph Eur are outlined in Figure 1A which is different from
Ch P procedure (Figure 1B). The Ph Eur Commission
decides to elaborate or revise a monograph, followed by the
WP to appoint a rapporteur for this specific monograph. The
appointed rapporteur will be responsible to prepare a draft
monograph based on scientific research and evaluation. Then
this draft monograph will be published in Pharmeuropa, an
official journal of the Ph Eur. The draft monograph is for
public inquiry and National Pharmacopeia Authorities
process the comments to the published draft monograph.
The WP examines the comments and revises the draft
monograph accordingly. Then the revised draft monograph
is proposed to Ph Eur Commissions for adoption (named
Table 1. Members of TCM working party at EDQM
Country Name Institute Expertise
Chairman
German Prof. Dr. G. Franz University Analytics
Members
Austria Prof. Dr. R. Bauer University Analytics
Austria Dr. R. Laenger EMA Microscopy
Germany Mr. E. Stoeger Industry
Belgium Prof. Dr. P. Duez University Analytics
Switzerland Dr. I.M. Bruentrup Industry
Switzerland Dr. Th. Lehmann OMCL Analytics
Switzerland Dr. E. Reich Industry TLC/TPTLC
Switzerland Dr. Sh. Wang-Tschen Industry
Germany Dr. M. Gasser Industry Analytics
Germany Dr. K. Wuthold Industry Analytics
France Prof. Dr. I. Fourasté University Microscopy
France Mr. R. Soussain OMCL
United Kingdom Mr. M. Whaley NPA
Italy Prof. Dr. A.R. Bilia University Analytics
The Netherlands Dr. M. Wang University Plant Biology
Poland Prof. Dr. K. Glowniak University Analytics
Turkey Prof. Dr. S. Harput University Analytics
Observes
Australia Prof. Dr. K. Chan University
China SATCM/NKL
Eighteen members plus one Chairman of TCM working party at EDQM, EMA: European medicinal agency, OMCL: Official
Medicines Control Laboratories, NPA: National Pharmacopeia Authority of UK SATCM/NKL: Chinese State administration of TCM/
National Key laboratory.
Start
Elaboraon Procedure of Ph Eur Monographs 
Decision from Ph Eur
Commission
WP: A rapporteur prepares
A dra monograph
For public Inquiry by 
member states
Publish in 
Pharmeuropa
Comments from Naonal 
Pharmacopeia authories
WP: examines and revises
the dra monograph
The dra monograph is 
proposed for adopon
Ph Eur Commission 
adopts the monograph
The Monograph is 
published
The monograph
becomes oﬃcial
Time Frame:
About 2 years
Figure 1A. Elaboration procedure of Ph Eur Monographs.
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COM document). With the approval of the Ph Eur commis-
sion the monograph will be published and becomes an
official Ph Eur Monograph (Figure 1A). The above men-
tioned procedure will usually take about two years to
complete an official monograph.
WORKING PROGRAM OF THE TCM
WORKING PARTY
As the Ph Eur Commission has stated that “monographs on
herbal drugs used in Traditional Chinese Medicine should be
developed to give a modern quality standard according to
European Pharmacopeia principle and to facilitate the
encourage use by practitioners for safe, authorized products”,
therefore the tasks of TCM WP are development of TCM
drug monographs that are frequently used in European
market. Herbal drugs used in Traditional Chinese Medicine
are found in several forms on the European market:
. Crude herbal drugs which have not been submitted to
any treatment other than physical treatment such as
cleaning, fragmentation and drying.
. Prepared (processed) herbal drugs which have been
subjected to one or more treatments such as exposure
to dry heat, boiling, cooking in various solutions etc.
. Herbal drugs occurring in a crude and processed form
. Preparations derived from herbal drugs which comprised
crude or processed drugs that have been involved in a
processing method which necessarily includes other ingre-
dients, such as vinegar, honey, ginger or other excipients.
At present, the TCM Working Party of the Ph Eur
Commission is only working on single TCM herbal drugs
in a crude and/or processed form. The preparation of the
TCM herbal drug monograph in the Ph Eur must always be
according to the Ph Eur Style and Technic Guidelines, using
ChP (editions 2005 and 2010) as basis but taking into
consideration the information from the WHO monographs
on selected medicinal plants, and the Hong Kong Chinese
Materia Medica Standard (HKCMMS) as well. Some com-
parisons between Ph Eur and Ch P was made previously[7].
In general a monograph of the actual Ph Eur 8th edition
consists of the following chapters: Definition, Identification,
Test, and Assay. There is a significant difference in structural
organization of all the monographs (see Figure 2) between Ph
Eur and Ch P, some information implemented in the ChP
are not present in the Ph Eur. Examples of these are the
herbal drugs prepared as slices, processing methods, ther-
apeutic property, flavor and taste, meridian tropism, actions,
indications, precaution, administrations and dosages. This is
because the Ph Eur only deals with quality related matters
and not with herbal drug indications and administration of
these. In the chapter Definition, the complete scientific name
of the plant (including genus, species, subspecies, variety and
author) is presented in Ph Eur. As an example, the major
difference in the chapter Definition of a monograph between
Ph Eur and Ch P is presented in Figure 3 using the newly
published monograph Polygoni multiflori radix. In general,
the Ph Eur will present the state of the drug such as if it
is whole, fragmented, peeled, fresh or dried. Wherever
possible, the minimum content of quantified constituents is
specified by Ph Eur. The major difference is that there is no
information on the systematic name of the respective plant
family, collection period and Chinese title, while the Latin
Working ﬂow chart of ChP
Experts commiee 2015
Public comments
2nd Experts commiee
Public comments
Execuve commiee
Signing of Chairman
Promulgaon by CFDA
New assembly
First dra monograph
Lab cross check
Lab draing
Arrangement for working task
Selecng monographs for ChP
Next Assembly 2020
Figure 1B. Working ﬂow chart of Ch P.
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name used for this herbal drug including the new systematic
name and possible synonyms of Polygoni multiflori radix and
minimum content of quality related marker compounds are
always provided in the Ph Eur (Figure 3). According to the
principles of Ph Eur, the identification of a herbal drug
should be relatively simple and be possible to be carried out
by e.g. community pharmacies with in general the combina-
tion of different methods that allow the identification of a
EP 8.0 Monograph CH 2010 Monograph
Scientific bridging
Title of the monograph
(with Chinese characters and Pinyin name)
DEFINITION
Minimum content %
IDENTIFICATION
A. Morphology: macroscopic, botanical
characters
B. Microscopic botanical characters 
powder only  
(with drawing)
C. TLC/HPTLC
With a schemac box  to show TLC  results
(ﬁngerprinng)
TESTS
classic tests e.g. ash, loss on drying  etc.
heavy metals, pescides, mycotoxins
If required: aristolochic acids, etc.
ASSAY
Quantave  assay for constuents marker 
compounds with known  therapeuc
acvity , inacve or analycal markers 
(with calculaon formula)
Reagents
origin and harvest me are presented
Descripon
Idenﬁcaon
(1) microscope study 
(2) TLC 
(3) HPLC 
Water
Extracves
Etc.
Assay
Prepared slices
Processing
Characters  and Flavour
Meridian tropism
Acons and Indicaons
Precauons
Administraon and dosage
Storage
Title of the monograph 
( with English and Lan names)
Figure 2A. Difference between herbal drug monographs in Ph Eur 8 and Ch P 2010.
Polygoni Multiflori Radix
( , Heshouwu)
Fleeceflower Root
Fleeceflower Root is the dried root 
tube of Polygoni Multiflori Thunb.
(Fam. Polygonaceae). The drug is 
collected in autumn and winter when 
leaves wither, removed from two 
ends, washed clean, and the large 
one cut into pieces, and then dried.
Fleeceflower Root
Polygoni multiflori Radix
DEFINITION
Whole or fragmented dried tuberous 
root of Fallopia multiflora (Thunb.) 
Haraldson (syn. Polygonum
multiflorum Thunb.)
Content: minimum 1.0 percent of 
2,3,5,4’-tetrahydroxystil-bene-2-O-
ß-glucoside (C20H22O9 Mr 406.4) ) 
(dried drug).
Differences:
- Root tuber vs. tuberous root
- no family name
- no collection period
- minimum content provided 
ChP. 2010
Ph Eur. 2014
Latin name
Latin name
Chinese name
English name
English name
Chinese name Missing
ChP vs. Ph Eur
Figure 2B. An example of TCM monograph in Ph Eur and Ch P.
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herbal drug without the use of expensive equipment. Both,
Ph Eur and Ch P have in common that they present finger
printing (TLC and/or HPTLC) and microscopic botanical
characteristics. In Ph Eur, a drawing of a microscopy study of
the powdered herbal drug and a box type table of results
from TLC/HPTLC are presented. However, there is no
description of the herbal drug prepared ready for decoction
also named “sliced drug” in Ph Eur. Therefore there is also
no microscopy study for this type of “sliced drug” in Ph Eur.
Within quality related issues, there is a large similarity in
scientific information between Ph Eur and Ch P (Figure 2).
For Ph Eur, wherever possible, an assay has to be included to
determine the constituents based on scientific data support-
ing therapeutic activity, such as an active therapeutic maker
or analytic marker compound.
Markers are chemically defined constituents or groups of
constituents which are of interest for control purpose
independent of whether they have any therapeutic activity.
Markers serve to calculate the quantity of herbal substance(s)
or herbal preparation (s) in the Herbal Medicinal Product
if that marker has been quantitatively determined in the
herbal substance(s) or herbal preparation(s) themselves.
There are two categories of markers: 1). Active markers: are
constituents or groups of constituents which are generally
accepted to contribute the therapeutic activity (with scientific
data support); 2). Analytical markers: are constituents or
groups of constituents that serve for analytical purposes. Both
type of markers are used in Ph Eur assays. The method used
for determination of the specific constituent is preferably by
LC or GC with a corresponding reference standard Chemi-
cal Reference Standard (CRS) or Herbal Reference Standard
(HRS) that is established by EDQM. The decision on the
choice of the compound as marker should be scientifically
justified but also be sustainable for practical purpose in
pharmacies. When a marker is used in a monograph of a
herbal drug in Ch P (edition 2005 or 2010), in principle, the
same marker is used in Ph Eur, except when the assay for this
marker is not sustainable or there is already an alternative
marker developed in Ph Eur. The analytical results obtained
may be presented differently in Ph Eur as compared to Ch P, as
is, for example, the case with HPLC assays.
In the Ph Eur chapter Test various quality control related
parameters are presented in Figure 4. The measurements of
contaminates such as heavy metals and mycotoxins are not
included in the monograph of ChP (ChP. 2005 and 2010).
Whilst Ph Eur has clearly stated the methods for measuring
aflatoxin B and ochratoxin A in herbal drugs and provides
limits for heavy metals (e.g. for lead the maximum is
5.0 ppm; for mercury the maximum is 0.1 ppm and for
cadmium the maximum is 1.0 ppm). A more detailed
description of Ph Eur’s work was reported previously[7].
Up to present, 43 TCM herbal drugs are adopted in Ph Eur
8th edition including supplements 8.1–8.4 (see Table 2) of
which 34 monographs are the results of the TCM working
party at EDQM. Two monographs (Lycii fructus (2612) and
Angelica dahurica root (2556)) were adopted by the Ph Eur
Commission and two more monographs (Anemarrhenae
rhizoma (2661) and Persicariae tinctoriae folium (2727))
were submitted to the Ph Eur Commission. There are
21 monographs published in the official journal of Ph Eur,
Pharmeuropa (Table 3).
INCLUSION OF PINYIN NAMES AND
SINOGRAMS IN THE TITLE OF
MONOGRAPHS
The English Title of a Monograph consists of the botanical
scientific name of the plant which is often a translation of the
Latin Title. The plant part used may be included in the title,
particularly where different Herbal Drugs are derived from
the same plant. In this case it is specified after the scientific
name of the plant.
One problem, which partly is resolved by the TCM WP is
the introduction of the Chinese Pinyin name as well as the
Sinograms for Traditional Chinese Herbal Drugs into the
Monographs of the Ph Eur, so that the specialists exactly
know what kind of herbs they are dealing with. Reintrodu-
cing Chinese Pinyin names will highlight to which
Quality 
Related
Parameters
Parameters related to Ph Eur Test
Heavy 
metals 
Pesticides 
Aflatoxin B1 
Ochratoxin A 
Loss on drying 
water content 
Foreign
matter 
Total ash 
Ash insoluble 
in HCL
Swelling
index 
Bitterness
value
Extractable 
matter
Figure 3. Parameters related to quality control in Chapter of Test in Ph Eur.
Quality Safety/Efficacy
EU Consumers
Ph  Eur Herbal Drug
Monograph
EMA Community
 Herbal Monograph 
Scientific guided safe 
use of TCM herbal medicine
Figure 4. The role of Ph Eur TCM monograph in Europe Ph Eur.
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therapeutic system the given herbal drug belongs. Most
European TCM practitioners always use Pinyin names of
these herbal drugs when writing a prescription, and conse-
quently the pharmacists throughout Europe should be
encouraged to become familiar with these Pinyin names.
When the original names are being removed from the title of
the Monograph, this will have an opposite effect. Having the
Pinyin names in the Monographs Title will facilitate the work
of the Pharmacist and there is no need for any additional
reference manuals beside the European Pharmacopoeia.
Since some herbal drugs originate from many continents (e.
g. Europe and China) the Pinyin name will clearly differ-
entiate between these herbs. For example for Angelica sp.
where several species are appearing in Europe and China
they can easily be differentiated by the Pinyin names.
The argument, that using the Chinese name for TCM Herbal
Drugs will lead to misidentification does not hold. Chinese
names will never replace the Latin names in the Monograph.
They do supply additional information important for exact
identification of different herbs of the same genus. Pinyin
names thus provide reliable criteria for differentiation in any
occasion of doubt. Due to all these reasons it was decided that
Pinyin names and Sinograms should appear somewhere in the
Ph Eur. The final decision was, that a special chapter should be
established, where the TCM Herbal Drugs are being listed with
the English-, Latin, French and Pinyin name plus Sinogram.
This chapter has been recently published (Pharmaeuropa 26.4,
also see table 2) and will be complemented by any addition of a
new TCM Herbal Drug which has been accepted by the
Commission ready for publication in Ph Eur.
Table 2. Monographs of Chinese Herbs Adopted in the European Pharmacopeia (Ph Eur)
Monograph
number Monograph number English title Pinyin Sinogram
2432 Acanthopanacis gracilistylicortex Acanthopanax bark wujiapi 五加皮
2554 Amomi fructus Amomum fruit sharen 砂仁
2555 Amomi fructus rotundus Round amomum fruit doukou 豆蔻
2661 Anemarrhenae asphodeloides rhizome Anemarrhena asphodeloides
rhizome
zhimu 知母
2556 Angelicae dahuricae radix Angelica dahurica root baizhi 白芷
2557 Angelicae pubescentis radix Angelica pubescens root duhuo 独活
2558 Angelicae sinensis radix Angelica sinensis root danggui 当归
2435 Astragali mongholici radix Astragalus mongholicus root huangqi 黄芪
2559 Atractylodis lanceae rhizoma Atractylodes lancea rhizome cangzhu 苍术
2560 Atractylodis macrocephalae rhizoma Atractylodes rhizome, largehead baizhu 白术
2561 Belamcandae chinensis rhizoma Belamcanda chinensis rhizome shegan 射干
2384 Bistortae rhizoma Bistort rhizome quanshen 拳参
2386 Carthami flos Safflower flower honghua 红花
2430 Citri reticulatae epicarpium et
mesocarpium
Mandarin epicarp and mesocarp chenpi 陈皮
2463 Clematidis armandii caulis Clematis armandii stem chuanmutong 川木通
2454 Coicis semen Coix seed yiyiren 薏苡仁
2473 Dioscoreae oppositifoliae rhizoma Dioscorea oppositifolia rhizome shanyao 山药
2563 Drynariae rhizoma Drynaria rhizome gusuibu 骨碎补
2564 Ecliptae herba Eclipta herb mohanlian 墨旱莲
2412 Eucommiae cortex Eucommia bark duzhong 杜仲
2451 Ephedrae herba Ephedra herb mahuang 麻黄
2452 Fraxini rhynchophyllae cortex Fraxinus rhynchophylla bark qinpi 秦皮
2566 Isatidis radix Isatis root banlangen 板蓝根
2612 Lycii fructus Barbary wolfberry fruit gouqizi 枸杞子
2567 Magnoliae officinalis cortex Magnolia officinalis bark houpo 厚朴
2568 Magnoliae officinalis flos Magnolia officinalis flower houpohua 厚朴花
2383* Notoginseng radix Notoginseng root sanqi 三七
2727 Persicariae tinctoriae folium Indigo plant leaf liaodaqingye 蓼大青叶
2477* Piperis fructus Pepper hujiao 胡椒
2453* Piperis longi fructus Long pepper bibo 荜茇
2433 Polygoni multiflori radix Fleeceflower root heshouwu 何首乌
2475 Poria Poria fuling 茯苓
2439 Prunellae spica Common selfheal fruit-spike xiakucao 夏枯草
2434* Puerariae lobatae radix Kudzuvine root gegen (yege) 葛根(野葛)
2483* Puerariae thomsonii radix Thomson kudzuvine root fenge 粉葛
2663 Salviae miltiorrhizae radix et rhizoma Salvia miltiorrhiza root and rhizome danshen 丹参
2385* Sanguisorbae radix Sanguisorba root diyu 地榆
2428 Schisandrae chinensis fructus Schisandra fruit wuweizi (bei
wuweizi)
五味子 (北五
味子)
2438 Scutellariae baicalensis radix Baical skullcap root huangqin 黄芩
2450 Sinomenii caulis Orientvine stem qingfengteng 青风藤
2639* Sophorae japonicae flos Sophora flower huaihua 槐花
2427* Sophorae japonicae flos immaturus Sophora flower-bud huaimi 槐米
2478* Stephaniae tetrandrae radix Fourstamen stephania root fenfangji (hanfangji) 粉防己 (汉防己)
*Herbal monographs were prepared before TCM WP by 13A and 13B groups at EDQM.
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SCIENTIFIC CHALLENGE FOR BRIDGING
PH EUR AND CH P:
Processing of TCM material medica
The materia medica of TCM mainly consists of herbal
products such as dried roots, rhizomes, stems, leaves, flowers,
fruits and seeds. The major application form in Traditional
Chinese Pharmacotherapy is a decoction. Due to the some-
times very voluminous herbal drugs, total drugs are not
suitable as raw material for decoctions; they should be
processed before usage. The processing of medicinal plant
materials has a history as long as Traditional Chinese
Medicine itself, The first complete guidebook of herbal
preparation goes back to the year 470. The importance of
the processing of materials has already been mentioned in the
Huang Di Nei Jing (The Yellow Emperor’s Internal Classic,
475-221 B.C.) and Shen Nong Ben Cao Jing (Divine Husband-
man’s Classic of the Materia Medica, c. 220 A.D.)[8] Depend-
ing on the therapeutic application, the same plant material can
be processed differently. In current TCM practice, all the
materials are strictly required to be properly processed before
using for therapeutic application. Most TCM herbal drugs
are in processed form and the purposes of processing are
highlighted[9]:
. Achieving drugs of consistent quality and amount for
constant and better effectiveness, better storability.
. Reducing toxic effects or undesired side effects.
. Modifying the effect of the herb by traditional, empiric
methods.
. Increasing the effect of the herb by traditional, empiric
methods
. Modifying molecular structure of the material used to
increase solubility.
. Removing unpleasant smells.
. Preparing drug material with completely different ther-
apeutic property as compared with raw the materials.
Understanding the metabolic changes during processing is of
great important for quality control of Chinese medicinal
herbal materials. Some intensive studies have been done
on the processing of e. g. Rehmannia glutinosa roots[10,11]. In
those studies, the role of processing was to modify the
therapeutic properties of the herbal drug Rehmannia gluti-
nosa roots that was associated with changes of metabolic
profiling during the processing. Effect of processing for
reduction of toxicity is another issue for TCM herbal drugs,
herewith an example of Aconiti radix is given: this refers to
the root part of the medicinal plant that belongs to the genus
of the family Ranunculaceae and is comprised of about 400
species of which 166 are endemic in China (http://www.
efloras.org/flora_page.aspx?flora_id=2). The most well-
known species is Aconitum napellus (Monk’s hood wolfs-
bane, aconite). Among them, only two species are used in
TCM; Aconitum carmichaeli Debx and Aconitum kusnezoffi
Reichb. The herbal medicines in the Ch P are Radix
Aconitum carmichaeli (Chuanwu, from the major root of
the species Aconitum carmichaeli Debx.) and its processed
form Radix Aconitum Preparata (Zhichuanwu), Radix Aco-
nitum Kusnezoffii (Caowu, from the root of Aconitum
Kusnezoffii Reichb), and its processed form Radix Aconitum
Kusnezoffii Preparata (Zhicaowu), Folium Aconitum Kusne-
zoffii (Caowuye) and the processed Radix Aconitum Lateralis
Preparata (Fuzi, the lateral root of the species Aconitum
carmichaeli Debx.)[9]. In the early ShengNong BenCao Jing,
Radix Aconitum carmichaeli (Chuanwu) was already
recorded as a high risk medicine. Diterpene alkaloids are
major chemical components of Radix Aconitum carmichaeli.
Aconitum roots, and some findings[12] demonstrated that
proper processing and multi-herbs formulation can reduce
the level of toxic components. This also explains that in
TCM, some herbal drugs, such as Aconitum and Ephedra
species are never used as single herb for intervention and that
aconite is only used when it is processed and in combination
with specific matched other herbs. Although some reports
about the metabolite changes during processing can be
identified in the literature, yet, many processed TCM drugs
still require scientific studies.
During processing, not only the metabolites changes are
important for quality control, but, various methods are
used for processing in TCM as well. Although there is a
significant difference between regions in China, in general
processing can be classified into 17 different categories[13]
(see Table 5.). Under each category there are still different
variations and in most case there are no scientific
parameters defined to the described categories. Moreover,
for the processing, various excipients are used. In Table 6
at least 10 different type of excipients used in TCM
processing are shown[13]. The excipients used in TCM
herbal drug processing are quite diverse and without
scientific parameters for quality descriptions as well.
The most important tasks from the TCM working Party of
the Ph Eur will be a joint cooperation between scientists in
the field to develop qualitative and quantitative parameters
for TCM drug processing procedures, standard operation
Table 3. Monographs of Chinese Herbs Published in
Pharmeuropa Editions 26.3, 26.4 and 27.1
Name of the TCM drugs
Number of Monograph/
in Pharmeuropa
Andrographis herb (2712)/26.3
Mandarin epicarp and mesocarp (2430)/26.3
Chinese goldthread rhizome (2715)/26.4
Eupatorium herb (2717)/26.4
Dioscorea oppositifolia rhizome (2473)/26.4
Ephedrae herba (2451)/26.4
Schisandrae chinensis fructus (2428)/26.4
Acori calami rizoma (2456)/27.1
Prunellae spica (2439)/27.1
Gastrodia rhizome (2721)/27.1
Peony root, white (2424)/27.1
Peony root, red (2425)/27.1
Gardeniae fructus (2565)/27.1
Polygoni cuspidatum rhizome and root (2724)/27.1
Lightyellow sophora root (2440)/27.1
Polygoni orientalis fructus (2726)/27.1
Zanthoxyli pericarpium (2656)/27.1
Codonopsidis radix (2714)/27.1
Eudoia fruit (2718)/27.1
Platycodonis radix (2660)/27.1
Uncaria stem with hooks (2729)/27.1
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protocols (SOP) and defined quality parameters for all
excipients used in these procedures.
COOPERATION BETWEEN SCIENTISTS
IN EUROPE AND CHINA
Since 2011 the Chinese State Administration of TCM
(SATCM) has established a formal cooperation between
EDQM, An agreement between both parties was signed in
June 2011. The purpose of this cooperation is to promote the
cooperation between SATCM of the People’s Republic of
China and the European Council represented by the EDQM.
A mutual cooperation of both parties was established aiming
to prepare the quality standards concerning a series of TCM
herbal drugs - herbal drug extracts. Both Parties intend to
speed up the establishment of high quality standards of TCM
in Europe in order to ensure the safety and quality of TCM
for the patients.
With the support of Mr. Daning Li from SATCM (former
vice director of SATCM), a National Key Laboratory for
TCM (NKL-TCM) was established from China side. Scien-
tists in China have joint in the preparation of TCM drug
monographs in the TCM working party of EDQM. Chinese
scientists supported the following aspects: provide scientific
literatures originated from Chinese modern and ancients
documents (translating from Chinese language to English
language), answer the questions related to TCM drug
processing, provide TCM drugs samples, participate in the
preparation of TCM monographs by conducting scientific
experimental works such as TLC and HPLC studies and
development of new quality markers for TCM herbal drugs.
From China side, a leading scientist in the field is visiting
TCM WP meeting on a regular basis, so that the interactions
between scientists from China and Europe are strengthened
considerably. Recently, SATCM also suggested new 15 herbal
drugs to be added to the Ph Eur TCM WP Working Program
(see Table 4).
ROLE OF TCM HERBAL DRUG
MONOGRAPHS IN EUROPE
TCM herbal drug monographs play an important role in
quality control for TCM practitioners who are prescribing
TCM herbal drugs for their patients/consumers. The present
situation in Europe is that the average European TCM
practitioner is using 300 TCM drugs in his/her daily practice
and the commercial importers provides up to 400 TCM
drugs. In European Chinese medicine clinics, there are
around 500 TCM drugs being used. The number of quality
monographs at this moment is still very limited and cannot
serve the needs to EU consumers. To meet the demands of
the consumers, much more quality monographs are needed.
Basically there are two types of monographs related to
herbal medicine/drugs in Europe. One of them are the
EDQM’s European Pharmacopeia monographs, which are
dealing with quality aspects of the herbal medicine/drugs
only. The other type of monograph, named “Community
Herbal monographs”, is prepared by the European Medicines
Agency (EMA) and is dealing with safety and efficiency of
herbal medicine/drugs. As both types of monograph play in
concert to contribute to the regulation of herbal medicines/
drugs in safe use of TCM drugs for consumers in Europe
(Figure 2), it is important to have frequently used TCM
drugs in the EU to be regulated by both, quality and safety/
efficiency rules. Up to now, there are only 10 EMA
“Community herbal monographs” for TCM products[14],
and already 43 TCM herbal drug monographs adopted by
the Ph Eur. The present article mainly focused on EDQM’s
herbal drug monographs, which will be the key for a quality
standard for herbal drugs used in Europe. This quality
standard can be applied to herbal raw materials that are
Table 4. New Chinese Herbs Working List Proposed by SATCM
Name of the TCM drugs
Proposed to Commission by
different member states
Arctii fructus Poland
Corydalis rhizoma Switzerland
Cyathulae radix The Netherlands
Eriobotryae folium Switzerland
Morindae officinalis Switzerland
Ophiopogonis radix The Netherlands
Persicae semen Switzerland
Peucedani radix Poland
Psoraleae fructus Germany
Pulsatillae radix Austria
Scrophulariae radix Austria
Typhae pollen Germany
Viticis fructus Austria
Achyranthis bidentat The Netherlands
Ganoderma The Netherlands
Table 5. Seventeen ancient processing methods (Zhang and Cai 1984)
No Descriptions No Descriptions
1 “Pao” heat on fire till smoking comes out 10. “Du” correcting the size of drugs
2 “Yan” heat till almost burnt: 11. “Fei” prepare drugs in fine powders
3 “Fu” dry on fire 12. “Fu” sop the drugs in water and then place in canister
4 “Zhi” Coated with otherness slightly heated by fire to dry 13. “Bang” to prepare the drug in thin sliced
5 “Wei” simmer heat of drugs in ash 14. “Sha” to reduce the drugs into small size till powders
6 “Chao” yellow fry, black fry, fry coke 15. “Shai” Sundry the drugs
7 “Duan” Put the herbs into fired carbon till it becomes red 16. “Bao” Exposure the drugs in direct sun shine
8 “Lian” heat on fire for a long time 17. “Lu” keep the drug outside inducing night
9 “Zhi” correcting properties of drugs with various methods
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used in pharmacy as well as to the preparation of the finished
herbal medicinal product during the manufacturing process
(e.g. under EU Good Manufacture Practice, GMP).
OUTLOOK FOR THE FUTURE DEVELOPMENT
OF TCM PRODUCTS IN EUROPE
The classical therapeutic dosage form in TCM therapy is the
hot water decoction of mostly a complex mixture of different
TCM herbal drugs. In order to facilitate the compliance of
these aqueous extracts, large scale decoctions at an industrial
level are spray dried, mixed with excipients and formulated
to the so called granules, which have recently been intro-
duced in large amounts to the European market. The
necessary quality parameters, however, of these TCM pro-
ducts is often not provided and sometimes rather doubtful,
since the preparation methods for these solid forms of
decoctions are not officially specified and hence, there are
often considerable differences in the overall composition
when comparing a classical decoction versus any granule
preparation of the commerce.
A very promising step forward for the general acceptance
of TCM products in the European Countries should be the
industrial production of defined and specified extracts from
single TCM herbs or even from complex mixtures of several
herbal drugs. These, by Ph Eur monographs qualified extracts
are the common basis for any legal registration by either the
respective National Authorities or even by the EMA in
London for all the European Member States. A first positive
example in this direction was the production and registration
of a defined saponin extract obtained from the TCM herbal
drug Dioscorea nipponica rhizome, which now is the basis
for the newly registered Phytomedicine DXXK in the
Netherlands[15].
Consequently, the Ph Eur Commission inaugurated the
elaboration of the respective quality monograph for this herbal
drug (Dioscorea nipponica rhizome) to be implemented in the
Ph Eur. The following step should be, to elaborate the
corresponding quality monograph of the Dioscorea nipponica
rhizome extract, and further to classify this new extract as a
standardised-, quantified- or other extract according to the
rules of the Ph Eur Monograph on Herbal Extracts. This
adoption of a first TCM herbal drug as the basis of a registered
European phytomedicine (DXXK) should be an important
signal for the Pharmaceutical Industry in China, to follow a
similar way, i.e., to produce defined herbal extracts with well-
established pharmacological and clinical data as the basis for
any registration in either individual countries of the EU or for
all EUMember States by the centralised registration procedure
via the EMA in London[16].
Following the future initiatives of the Chinese Pharmaceu-
tical Industry, the Ph Eur will react accordingly by elaborat-
ing the respective Quality Monographs for both, the TCM
herbal drug and the respective defined extract following the
rules and guidelines specified for herbal drugs and herbal
drug preparations (extracts). It can be hoped that in the near
future intensified contacts and collaborations between
Chinese and European Officials and between Chinese and
European Pharmaceutical Industries can be inaugurated in
order to create most efficient new TCM phytomedicines for
the patients in Europe.
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